StockNews.AISignal intelligenceSignal detail
Source-backed analysis, the reasoning behind the signal, and its market context.
Bullish near-term on beat-and-raise; watch for upside into 1–3 months as pipeline catalysts mature.
What happened and why it matters
Eli Lilly delivered a strong Q2 2026, with revenue of $23.0B (+48% YoY) driven by Mounjaro and Zepbound, and both GAAP and non-GAAP EPS beating prior guidance. The company raised 2026 revenue guidance to $85–$87B and non-GAAP EPS to $35.50–$36.50, partially offset by $3.03B in acquired IPR&D charges. Regulatory and pipeline progress, plus aggressive manufacturing expansion, position Lilly for continued growth into 2027.
The beat-and-raise earnings narrative, combined with expanding Mounjaro/Zepbound franchises and multiple regulatory milestones, typically prompts short-term upside. However, elevated IPR&D charges temper GAAP earnings, so the upside may be moderated by profit-quality concerns and optics around acquisitions. Historically, Lilly has shown stock moves on strong guidance and pipeline news, supporting a near-term rally.
Q2 2026 revenue $23.0B, up 48% YoY, led by Mounjaro/Zepbound.
GAAP EPS $7.94; non-GAAP EPS $8.38; includes $3.03B acquired IPR&D charges.
2026 revenue guidance raised to $85–$87B; non-GAAP EPS $35.50–$36.50.
Regulatory progress: CHMP recommends Jaypirca; FDA approves EBGLYSS (lebrikizumab) for AD.
Mounjaro $9.9B globally; Zepbound US $4.9B; Indiana capex $4.5B expansion.
Category: Earnings. The release centers on quarterly results, updated guidance, and pipeline/regulatory progress, all of which are core valuation drivers for LLY and its growth trajectory in obesity, diabetes, immunology, and oncology.
More AI-analyzed coverage connected to this story